Latest news with #MorganStanleyGlobalHealthcareConference
Business Wire
5 days ago
- Business
- Business Wire
Bausch + Lomb to Participate in Upcoming Investor Conferences
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in investor meetings at the J.P. Morgan conference. Chairman of the Board and Chief Executive Officer Brent Saunders and Sam Eldessouky will participate in a fireside chat at the Morgan Stanley conference. A live webcast of the Morgan Stanley fireside chat will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. © 2025 Bausch + Lomb
Business Wire
17-07-2025
- Business
- Business Wire
Geneoscopy to Participate in Upcoming Investor Conferences
ST. LOUIS, Mo.--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that members of its management team will be participating in the following investor conferences: Morgan Stanley Global Healthcare Conference in New York City September 8, 2025 - September 10, 2025 Bank of America Healthcare Trailblazers Private Company Conference in Boston September 17, 2025 - September 18, 2025 UBS Global Healthcare Conference in Palm Beach Gardens November 9, 2025 - November 12, 2025 Stifel Healthcare Conference in New York City November 11, 2025 - November 13, 2025 One-on-one meetings with company management are available during the conferences upon request. About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn.
